Atossa Therapeutics, Inc.
ATOS
$0.823
-$0.011-1.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.53M | 13.51M | 13.12M | 13.15M | 13.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.06M | 27.62M | 29.49M | 30.57M | 31.26M |
| Operating Income | -28.06M | -27.62M | -29.49M | -30.57M | -31.26M |
| Income Before Tax | -26.34M | -25.50M | -26.91M | -25.91M | -29.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.34 | -25.50 | -26.91 | -25.91 | -29.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.34M | -25.50M | -26.91M | -25.91M | -29.69M |
| EBIT | -28.06M | -27.62M | -29.49M | -30.57M | -31.26M |
| EBITDA | -28.04M | -27.60M | -29.46M | -30.55M | -31.24M |
| EPS Basic | -0.21 | -0.20 | -0.21 | -0.21 | -0.24 |
| Normalized Basic EPS | -0.12 | -0.12 | -0.13 | -0.13 | -0.13 |
| EPS Diluted | -0.21 | -0.20 | -0.21 | -0.21 | -0.24 |
| Normalized Diluted EPS | -0.12 | -0.12 | -0.13 | -0.13 | -0.13 |
| Average Basic Shares Outstanding | 507.29M | 503.44M | 502.12M | 502.14M | 503.03M |
| Average Diluted Shares Outstanding | 507.29M | 503.44M | 502.12M | 502.14M | 503.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |